NeuroBo Pharmaceuticals’ DA-1726 shows promising results in pre-clinical obesity treatment studies
NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology firm, announced promising pre-clinical data for DA-1726, a novel oxyntomodulin (OXM) analog functioning as a dual agonist ... Read More
NeuroBo, Gemphire merger wrapped up to form neurodegenerative disease company
NeuroBo Pharmaceuticals, a Boston-based clinical-stage pharma company, has wrapped up its previously announced merger with Gemphire Therapeutics, a Michigan-based clinical-stage biopharma company focused on developing ... Read More